Redmile Group’s Entrada Therapeutics TRDA Stock Holding History

Redmile Group’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-560,971	Closed	-$7.99M	–	67
2024 Q2	$7.99M	Sell	560,971 -722,764	-56%	-$10.3M	0.48%	42
2024 Q1	$18.2M	Hold	1,283,735	–	–	0.67%	41
2023 Q4	$19.4M	Sell	1,283,735 -265	-0%	-$3.93K	0.69%	39
2023 Q3	$20.3M	Sell	1,284,000 -27,572	-2%	-$434K	0.97%	31
2023 Q2	$19.9M	Sell	1,311,572 -520,036	-28%	-$7.16M	0.76%	39
2023 Q1	$26.6M	Sell	1,831,608 -22,500	-1%	-$300K	1.15%	31
2022 Q4	$25.1M	Sell	1,854,108 -100,311	-5%	-$1.76M	1.03%	29
2022 Q3	$30.8M	Hold	1,954,419	–	–	1.19%	30
2022 Q2	$23.8M	Hold	1,954,419	–	–	0.91%	32
2022 Q1	$18.4M	Sell	1,954,419 -1	-0%	-$11	0.57%	42
2021 Q4	$33.5M	Buy	+1,954,420	New	+$47.4M	0.76%	37

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Redmile Group's TRDA Position: Q3 2024 in Review

Redmile Group sold out of Entrada Therapeutics (TRDA) in Q3 2024, closing a stake of 560,971 shares — an estimated $7.99M sold.

Redmile Group first reported a position in TRDA in Q4 2021 and held it in 11 quarters. The position peaked at $33.5M in Q4 2021. 97 funds tracked by Wall St. Rank hold TRDA as of Q3 2024.

Redmile Group reported no remaining Entrada Therapeutics position as of Q3 2024 after selling out during the quarter.
Redmile Group sold 560,971 Entrada Therapeutics shares in Q3 2024, an estimated $7.99M.
Redmile Group first reported a position in Entrada Therapeutics in Q4 2021 and held it in 11 quarters.
Redmile Group's Entrada Therapeutics position peaked at $33.5M in Q4 2021.
97 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2024.

Based on Redmile Group's 13F filing for Q3 2024, filed 14 Nov 2024.